|
1）Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma-COPD Overlap Syndrome （ACOS）. The global strategy for asthma management and prevention and the global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. 2014. http://www.ginasthma.org/local/uploads/files/AsthmaCOPDOverlap.pdf
|
|
|
|
|
2）日本アレルギー学会喘息ガイドライン専門部会．喘息予防・管理ガイドライン2015．東京：協和企画；2015
|
|
|
|
|
|
3）Elias J. The relationship between asthma and COPD: lessons from transgenic mice. Chest. 2004; 126: 111S-6S
|
|
|
|
|
4）日本呼吸器学会COPDガイドライン第4版作成委員会．COPD（慢性閉塞性肺疾患）診断と治療のためのガイドライ第4版．大阪：メディカルレビュー社；2013
|
|
|
|
|
|
5）Zeki AA, Schivo M, Chan A, et al. The Asthma-COPD overlap syndrome: a common clinical problem in the elderly. Allergy. 2011; 2011: 861926
|
|
|
|
|
|
6）Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med. 2008; 359: 1543-54
|
|
|
|
|
|
7）Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013; 107: 1538-46
|
|
|
|
|
|
8）Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium （SPARK）: a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013; 1: 199-209
|
|
|
|
|
|
9）Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012; 40: 1106-14
|
|
|
|
|
|
10）Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003; 124: 474-81
|
|
|
|
|
|
11）Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015; 385: 899-909
|
|
|
|
|
|
12）Bolton CE, Bush A, Hurst JR, et al. Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice. Thorax. 2012; 67: 1110
|
|
|
|
|
|
13）Svanes C, Sunyer J, Plana E, et al. Early life origins of chronic obstructive pulmonary disease. Thorax. 2010; 65: 14-20
|
|
|
|
|
|
14）Beyer D, Mitfessel H, Gillissen A. Maternal smoking promotes chronic obstructive lung disease in the offspring as adults. Eur J Med Res. 2009; 14 Suppl 4: 27-31
|
|
|
|
|
|
15）Tran H, Tai A, Roberts M, et al. COPD: an outcome of childhood asthma? Eur Respir J. 2010; 36: 1016s
|
|
|
|
|
|
16）Phelan PD, Robertson CF, Olinsky A. The Melbourne asthma study: 1964-1999. J Allergy Clin Immunol. 2002; 109: 189-94
|
|
|
|
|
|
17）James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study - The effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005; 171: 109-14
|
|
|
|
|
|
18）Tsoumakidou M, Tzanakis N, Kyriakou D, et al. Inflammatory cell profiles and T-lymphocyte subsets in chronic obstructive pulmonary disease and severe persistent asthma. Clin Exp Allergy. 2004; 34: 234-40
|
|
|
|
|
|
19）Fujimoto K, Kubo K, Yamamoto H, et al. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest. 1999; 115: 697-702
|
|
|
|
|
|
20）Chanez P, Vignola AM, OShaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med. 1997; 155: 1529-34
|
|
|
|
|
|
21）Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000; 356: 1480-5
|
|
|
|
|
|
22）Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011; 48: 279-85
|
|
|
|
|
|
23）Silva GE, Sherrill DL, Guerra S, et al. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004; 126: 59-65
|
|
|
|
|
|
24）Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011; 12: 127
|
|
|
|
|
|
25）Meyer PA, Mannino DM, Redd SC, et al. Characteristics of adults dying with COPD. Chest. 2002; 122: 2003-8
|
|
|
|
|
|
26）Shaya FT, Du DY, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest. 2008; 134: 14-9
|
|
|
|
|
|
27）Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009; 64: 728-35
|
|
|
|
|
|
28）赤澤 晃．電話調査法による全国全年齢階級喘息有病率調査．平成16年度厚生労働科学研究補助金；免疫アレルギー疾患予防・治療研究事業研究報告書. 2006
|
|
|
|
|
|
29）橋本 修，平田一人，浅野雅之．慢性閉塞性肺疾患（COPD）患者および喘息合併患者における治療の現状—インターネット調査より．Prog Med. 2013; 33: 355-62
|
|
|
|
|
30）足立 満，松永和人，一ノ瀬正和．本邦における高齢者喘息の現状と課題. アレルギー・免疫．2009; 16: 248-59
|
|
|
|
|
|
31）Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008; 63: 761-7
|
|
|
|
|
|
32）Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009; 34: 812-8
|
|
|
|
|
|
33）Fingleton J, Travers J, Williams M, et al. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. J Allergy Clin Immunol. 2015. Mar 4. pii: S0091-6749（15）00103-7
|
|
|
|
|
|
34）Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014; 44: 341-50
|
|
|
|
|
|
35）Bujarski S, Parulekar AD, Sharafkhaneh A, et al. The asthma COPD overlap syndrome （ACOS）. Curr Allergy Asthma Rep. 2015; 15: 509
|
|
|
|
|
|
36）Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013; 6: 197-219
|
|
|
|
|
|
37）Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000; 160: 1683-9
|
|
|
|
|
|
38）Tamada T, Sugiura H, Takahashi T, et al. Biomarker-based detection of ACOS in COPD populations. Int J Chron Obstruct Pulmon Dis. 2015; 10: 2169-76
|
|
|
|
|
|
39）Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. New Engl J Med. 2012; 367: 1198-207
|
|
|
|
|